Target‐mediated drug disposition modeling of an anti‐TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics-Reference-Cited by-同舟云学术

Target‐mediated drug disposition modeling of an anti‐TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics

Published:2021-05-17 Issue:6 Volume:19 Page:1425-1435
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Kwak Eun‐young¹,Kim Min ju¹,Park Jin hyun¹,Jung Ha wook¹,Jung Myung Eun²

Affiliation:

1. Department of GC Pharma R&D Center GC Pharma Gyeonggi‐do Korea

2. Bio Division DIGMBIO Gyeonggi‐do Korea

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15244

Reference32 articles.

1. Tissue factor pathway inhibitor: structure-function

2. Tissue factor pathway inhibitor and the current concept of blood coagulation

3. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis

4. Extrinsic pathway inhibitor–the key to feedback control of blood coagulation initiated by tissue thromboplastin;Sandset PM;Haemostasis,1991

5. Plasma Tissue Factor Pathway Inhibitor (TFPI) Levels in Healthy Subjects and Patients with Hemophilia A and B

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives;Biomolecules;2024-07-15

2. L’ère des nanocorps et anticorps thérapeutiques en hémostase;Revue Francophone des Laboratoires;2024-03

3. New directions to develop therapies for people with hemophilia;Expert Review of Hematology;2023-03-08

4. Early stage clinical trials for the treatment of hemophilia A;Expert Opinion on Investigational Drugs;2022-11-02

5. Updates on Novel Non-Replacement Drugs for Hemophilia;Pharmaceuticals;2022-09-23